REFRACTORY ACUTE MYELOID LEUKEMIA

This early-stage study is testing the safety and best dose of a two-drug combination for people with aggressive forms of blood cancer (myelodysplastic syndrome or acute myeloid leukemia) that have returned or not responded to prior treatments. The trial combines a chemotherapy dr…

This early-stage study is testing the safety and best dose of a drug called palbociclib, given alone and in combination with other medications, for adults with acute leukemia that has come back or hasn't responded to previous treatments. The main goal is to find out what side eff…

This early-stage study is testing a new combination of three drugs—navtemadlin, decitabine, and venetoclax—for adults with acute myeloid leukemia (AML) that has returned, is resistant to treatment, or is newly diagnosed in patients who cannot tolerate intensive chemotherapy. The …

This early-stage study is testing whether two drugs—entrectinib and ASTX727—can be safely combined to treat acute myeloid leukemia (AML) that has returned or resisted treatment and has a specific genetic change (TP53 mutation). The trial involves about 13 adults and aims to find …

This early-stage study is testing a new drug called uproleselan, given with two standard chemotherapy drugs, for children and teenagers with aggressive forms of leukemia that have come back or stopped responding to treatment. The main goals are to find the safest dose and see how…

This study is testing whether combining three different cancer drugs can better control two aggressive types of blood cancer: Philadelphia chromosome-positive acute myeloid leukemia (AML) and advanced chronic myeloid leukemia (CML). The trial will enroll about 20 adults with thes…

This study is testing whether two oral cancer drugs, venetoclax and decitabine, can help control a fast-growing blood cancer called acute myeloid leukemia (AML) in adults for whom prior treatments have stopped working. The goal is to see if this combination can reduce cancer cell…

This study is testing a drug called enasidenib in children and young adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to standard chemotherapy. The goal is to see if the drug is safe for children and how their bodies process it. The …

This study is testing a combination of two drugs for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or hasn't responded to other treatments. The goal is to see if the combination is safe and effective at controlling the dis…

This study is testing if a pill called olaparib can help control advanced blood cancers (acute myeloid leukemia or myelodysplastic syndrome) that have come back or haven't responded to standard treatments. It is for adults whose cancer has a specific genetic change called an IDH …

This study is testing whether two oral drugs, venetoclax and ASTX727, can help control acute myeloid leukemia (AML). It is for adults whose AML has come back or hasn't responded to prior treatment, or for older, newly diagnosed patients who cannot tolerate strong chemotherapy. Th…

This early-stage trial is testing a new immunotherapy drug called flotetuzumab in children and young adults whose acute myeloid leukemia (AML) has come back or hasn't responded to other treatments. The main goals are to find the safest dose and understand the side effects. The dr…

This study is testing the safety and best dose of an experimental drug, nintedanib, when combined with an approved drug, azacitidine. It is for older adults with a specific type of acute myeloid leukemia who are not candidates for or choose to avoid intensive chemotherapy. The ma…

This study is testing if adding a new drug called veliparib to a standard two-drug chemotherapy works better for people with advanced blood cancers that have spread and are hard to treat. It will compare the two-drug combo with the three-drug combo in about 25 participants to see…

This early-stage study is testing a new oral drug called M3814 in combination with a standard chemotherapy regimen (MEC) for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The main goals are to find the safest and most effective do…

This study is testing if adding the drug sorafenib to standard chemotherapy drugs (busulfan and fludarabine) is safe and effective for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The goal is to better prepare patients for a stem cell …

This early-stage study is testing the safety and best dose of a new three-drug combination for adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to prior treatments. The goal is to see if adding the drug regorafenib to two exis…

This early-stage study is testing a new type of cellular therapy for adults with acute myeloid leukemia or a related blood cancer that has come back or not responded to standard treatments. Doctors collect a patient's or donor's immune cells, genetically modify them in a lab to b…

This study is testing a new combination of oral drugs (selinexor and venetoclax) with standard chemotherapy for children and young adults whose acute myeloid leukemia (AML) has returned or hasn't responded to previous treatments. The main goal is to find the safest and most effec…

This early-phase study is testing the safety and best dose of a two-drug combination (enasidenib and cobimetinib) for adults with acute myeloid leukemia (AML) that has come back or stopped responding to other treatments. The drugs work by blocking specific signals that help the c…